The mRNA Cancer Vaccine: The Dawn of Personalised Oncology
On August 19, 2026, the history of cancer treatment acquired a new chapter. Merck and Moderna announced that their personalised mRNA cancer vaccine had succeeded in a landmark Phase 3 trial involving more than 1,100 people with high-risk melanoma. The treatment significantly reduced the chances that the cancer would return or spread.
For decades, scientists dreamed of making a cancer vaccine tailored to an individual tumour. Now, that idea has cleared the most important hurdle in clinical medicine: a large, late-stage trial.
The treatment, called intismeran autogene, could mark the beginning of personalised oncology as a new standard of cancer care.
